MASIMO CORP's ticker is MASI and the CUSIP is 574795100. A total of 349 filers reported holding MASIMO CORP in Q2 2024. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
About MASIMO CORP
Masimo Corp is a medical technology company that specializes in non-invasive patient monitoring devices. The company was founded in 1989 and is headquartered in Irvine, California. Masimo's products are used in hospitals, clinics, and other healthcare settings around the world.
One of Masimo's most well-known products is the Masimo SET pulse oximetry technology, which measures oxygen saturation in the blood. This technology has been shown to be more accurate than other pulse oximetry technologies, and is used in a wide range of medical applications.
In addition to pulse oximetry, Masimo also offers a range of other monitoring technologies, including capnography, brain function monitoring, and acoustic respiration rate monitoring. These technologies are designed to help healthcare providers monitor patients more effectively and improve patient outcomes.
Masimo has a strong track record of innovation, with over 1,000 patents and patent applications worldwide. The company invests heavily in research and development, and has a team of over 500 engineers and scientists working to develop new technologies and improve existing ones.
Overall, Masimo is a leading player in the medical technology industry, with a strong focus on innovation and improving patient outcomes. As the healthcare industry continues to evolve, Masimo is well-positioned to continue to grow and expand its product offerings.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,944,000 | +6.1% | 12,459 | +1.2% | 0.01% | -7.7% |
| Q3 2019 | $1,832,000 | +19.4% | 12,315 | +19.6% | 0.01% | +18.2% |
| Q2 2019 | $1,534,000 | -11.7% | 10,295 | -18.0% | 0.01% | -15.4% |
| Q1 2019 | $1,737,000 | +46.8% | 12,560 | +13.9% | 0.01% | +18.2% |
| Q4 2018 | $1,183,000 | -6.0% | 11,027 | +9.0% | 0.01% | 0.0% |
| Q3 2018 | $1,259,000 | +12.8% | 10,120 | -20.3% | 0.01% | +10.0% |
| Q2 2018 | $1,116,000 | 0.0% | 12,698 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $1,116,000 | +27.0% | 12,698 | +22.5% | 0.01% | +25.0% |
| Q4 2017 | $879,000 | +5.3% | 10,368 | +7.4% | 0.01% | -11.1% |
| Q3 2017 | $835,000 | +3.1% | 9,650 | +8.5% | 0.01% | -10.0% |
| Q2 2017 | $810,000 | +11.0% | 8,891 | +13.6% | 0.01% | +11.1% |
| Q1 2017 | $730,000 | +2.4% | 7,826 | -26.0% | 0.01% | -10.0% |
| Q4 2016 | $713,000 | +1108.5% | 10,576 | +957.6% | 0.01% | +900.0% |
| Q3 2016 | $59,000 | +11.3% | 1,000 | +0.3% | 0.00% | 0.0% |
| Q2 2016 | $53,000 | +253.3% | 997 | +173.2% | 0.00% | – |
| Q1 2016 | $15,000 | +15.4% | 365 | +20.9% | 0.00% | – |
| Q4 2015 | $13,000 | +116.7% | 302 | +94.8% | 0.00% | – |
| Q3 2015 | $6,000 | -14.3% | 155 | -15.8% | 0.00% | – |
| Q2 2015 | $7,000 | +75.0% | 184 | +41.5% | 0.00% | – |
| Q1 2015 | $4,000 | -20.0% | 130 | -28.6% | 0.00% | – |
| Q4 2014 | $5,000 | – | 182 | +18100.0% | 0.00% | – |
| Q3 2013 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2013 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ensemble Capital Management | 242,997 | $57,362,000 | 6.74% |
| Ownership Capital B.V. | 1,352,329 | $319,231,000 | 6.64% |
| Blue Whale Capital LLP | 97,100 | $22,921,000 | 4.43% |
| MARTIN CURRIE LTD | 313,810 | $74,078,000 | 3.83% |
| Parian Global Management LP | 47,638 | $11,245,000 | 3.57% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 195,600 | $46,173,000 | 3.46% |
| GENEVA CAPITAL MANAGEMENT LLC | 541,812 | $127,900,000 | 2.64% |
| RTW INVESTMENTS, LP | 450,390 | $106,319,000 | 2.56% |
| CROWN ADVISORS MANAGEMENT, INC. | 15,000 | $3,541,000 | 2.30% |
| Parkman Healthcare Partners LLC | 35,000 | $8,262,000 | 2.19% |